About Heat Biologics
Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer by harnessing the power of CD8+ "Killer" T-cells, the immune cells crucial in tumor cell killing. Heat’s T-Cell Activation Platform ("TCAP") is designed to turn "cold" tumors "hot" and is administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 (ImPACT) is the company’s first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Heat’s ComPACT technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. Currently, patient enrollment is ongoing in a Phase 2 clinical trial with HS-110 for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®) and with Merck's pembrolizumab (Keytruda®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. Heat’s pipeline also includes numerous pre-clinical programs at various stages of development.
State of Ownership
Head of Sales and Marketing, Conversis